19.24
price down icon1.89%   -0.37
after-market アフターアワーズ: 19.24
loading
前日終値:
$19.61
開ける:
$19.98
24時間の取引高:
54,516
Relative Volume:
0.49
時価総額:
$494.95M
収益:
$26.00M
当期純損益:
$-219.71M
株価収益率:
-0.3863
EPS:
-49.8
ネットキャッシュフロー:
$-51.37M
1週間 パフォーマンス:
-2.19%
1か月 パフォーマンス:
-3.07%
6か月 パフォーマンス:
+29.30%
1年 パフォーマンス:
-11.12%
1日の値動き範囲:
Value
$19.22
$19.98
1週間の範囲:
Value
$19.22
$20.00
52週間の値動き範囲:
Value
$11.66
$41.87

Cartesian Therapeutics Inc Stock (RNAC) Company Profile

Name
名前
Cartesian Therapeutics Inc
Name
セクター
Healthcare (1169)
Name
電話
301-348-8698
Name
住所
7495 NEW HORIZON WAY, FREDERICK
Name
職員
38
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
RNAC's Discussions on Twitter

RNAC を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
RNAC
Cartesian Therapeutics Inc
19.24 494.95M 26.00M -219.71M -51.37M -49.80
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-19 開始されました BTIG Research Buy
2024-08-06 開始されました TD Cowen Buy
2024-07-02 ダウングレード Oppenheimer Outperform → Perform
2024-06-04 開始されました Oppenheimer Outperform
2024-05-24 開始されました Mizuho Buy
2024-04-23 繰り返されました H.C. Wainwright Buy
2024-04-23 開始されました Leerink Partners Outperform
2023-08-18 ダウングレード SVB Securities Outperform → Market Perform
2022-06-14 繰り返されました Needham Buy
2022-06-06 開始されました SVB Leerink Outperform
2021-06-15 開始されました BTIG Research Buy
2021-01-26 アップグレード Mizuho Neutral → Buy
2020-10-01 ダウングレード Mizuho Buy → Neutral
2020-10-01 ダウングレード William Blair Outperform → Mkt Perform
2020-06-12 ダウングレード Stifel Buy → Hold
2020-04-28 開始されました H.C. Wainwright Buy
2020-01-29 開始されました Cantor Fitzgerald Overweight
2020-01-21 開始されました William Blair Outperform
2018-06-27 開始されました Janney Buy
2017-03-30 繰り返されました UBS Buy
すべてを表示

Cartesian Therapeutics Inc (RNAC) 最新ニュース

pulisher
Feb 18, 2025

Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq

Feb 18, 2025
pulisher
Feb 18, 2025

Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times

Feb 18, 2025
pulisher
Feb 18, 2025

Major mRNA Cell Therapy Player Sets Ambitious 3-Conference Roadshow: Key Dates Inside - StockTitan

Feb 18, 2025
pulisher
Feb 15, 2025

Mirae Asset Global Investments Co. Ltd. Has $82,000 Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

What is Leerink Partnrs' Estimate for RNAC FY2024 Earnings? - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.86 - MarketBeat

Feb 13, 2025
pulisher
Feb 12, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Analysts - Defense World

Feb 12, 2025
pulisher
Feb 11, 2025

Leerink Partnrs Issues Optimistic Estimate for RNAC Earnings - Defense World

Feb 11, 2025
pulisher
Feb 09, 2025

RNACCartesian Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025
pulisher
Feb 07, 2025

What is Leerink Partnrs’ Forecast for RNAC FY2029 Earnings? - Armenian Reporter

Feb 07, 2025
pulisher
Feb 06, 2025

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Feb 06, 2025
pulisher
Feb 06, 2025

Cartesian Therapeutics Issues Strategic Employee Stock Options Worth $3.3MInside Details - StockTitan

Feb 06, 2025
pulisher
Jan 31, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from HC Wainwright - MarketBeat

Jan 31, 2025
pulisher
Jan 28, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Given “Buy” Rating at Needham & Company LLC - Defense World

Jan 28, 2025
pulisher
Jan 28, 2025

Cartesian Therapeutics Announces FDA Special Protocol - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Cartesian Therapeutics Secures FDA SPA Agreement For Phase 3 AURORA Trial - Nasdaq

Jan 27, 2025
pulisher
Jan 27, 2025

Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from Needham & Company LLC - MarketBeat

Jan 27, 2025
pulisher
Jan 27, 2025

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis - The Manila Times

Jan 27, 2025
pulisher
Jan 27, 2025

Cartesian Therapeutics, Inc. Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis - Marketscreener.com

Jan 27, 2025
pulisher
Jan 27, 2025

FDA Grants Special Protocol Assessment for Cartesian's Myasthenia Gravis Treatment - StockTitan

Jan 27, 2025
pulisher
Jan 22, 2025

Barclays PLC Boosts Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 22, 2025
pulisher
Jan 18, 2025

Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Target Price at $42.86 - Defense World

Jan 18, 2025
pulisher
Jan 17, 2025

Cartesian Therapeutics: Need To Wait For More Data For Its Novel mRNA Therapies - Seeking Alpha

Jan 17, 2025
pulisher
Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock By Investing.com - Investing.com Nigeria

Jan 15, 2025
pulisher
Jan 15, 2025

Cartesian Therapeutics director Timothy Springer acquires $366k in stock - Investing.com India

Jan 15, 2025
pulisher
Jan 15, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Consensus PT from Brokerages - MarketBeat

Jan 15, 2025
pulisher
Jan 14, 2025

Cartesian Therapeutics’ (RNAC) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Needham & Company LLC Reiterates "Buy" Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Cartesian Therapeutics Sets 2025 Strategy for Descartes-08 - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Cartesian Therapeutics Highlights Progress and 2025 - GlobeNewswire

Jan 13, 2025
pulisher
Jan 13, 2025

Cartesian's Descartes-08 Shows Strong Phase 2b Results in Myasthenia Gravis, Phase 3 Trial Planned - StockTitan

Jan 13, 2025
pulisher
Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen R&D, Immunovant - The Globe and Mail

Jan 08, 2025
pulisher
Jan 08, 2025

Myasthenia Gravis Market Poised for Significant Growth from - openPR

Jan 08, 2025
pulisher
Jan 08, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock By Investing.com - Investing.com Australia

Jan 08, 2025
pulisher
Jan 08, 2025

Geode Capital Management LLC Raises Stock Position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World

Jan 08, 2025
pulisher
Jan 08, 2025

Cartesian therapeutics COO Emily English sells $30,149 in stock By Investing.com - Investing.com Nigeria

Jan 08, 2025
pulisher
Jan 08, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares By Investing.com - Investing.com South Africa

Jan 08, 2025
pulisher
Jan 08, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock By Investing.com - Investing.com Canada

Jan 08, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics CMO Milos Miljkovic sells $31,541 in stock By Investing.com - Investing.com Nigeria

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics CFO sells shares worth $134,035 - Investing.com India

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Sells $40,412.24 in Stock - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CTO Metin Kurtoglu Sells 2,458 Shares - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Insider Milos Miljkovic Sells 948 Shares - MarketBeat

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics chief scientific officer sells $42,782 in stock - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Cartesian Therapeutics CTO Metin Kurtoglu sells $81,790 in stock - Investing.com

Jan 07, 2025
pulisher
Jan 07, 2025

Carsten Brunn sells $289,764 in Cartesian Therapeutics shares - Investing.com

Jan 07, 2025

Cartesian Therapeutics Inc (RNAC) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):